Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Short-term Investments (2016 - 2017)

Historic Short-term Investments for Adma Biologics (ADMA) over the last 3 years, with Q4 2017 value amounting to $1.5 million.

  • Adma Biologics' Short-term Investments fell 7217.16% to $1.5 million in Q4 2017 from the same period last year, while for Dec 2017 it was $1.5 million, marking a year-over-year decrease of 7217.16%. This contributed to the annual value of $1.5 million for FY2017, which is 7217.16% down from last year.
  • According to the latest figures from Q4 2017, Adma Biologics' Short-term Investments is $1.5 million, which was down 7217.16% from $845389.0 recorded in Q3 2017.
  • Adma Biologics' Short-term Investments' 5-year high stood at $6.4 million during Q4 2015, with a 5-year trough of $245000.0 in Q1 2017.
  • For the 3-year period, Adma Biologics' Short-term Investments averaged around $2.5 million, with its median value being $1.2 million (2017).
  • Per our database at Business Quant, Adma Biologics' Short-term Investments crashed by 1535.75% in 2016 and then crashed by 7217.16% in 2017.
  • Over the past 3 years, Adma Biologics' Short-term Investments (Quarter) stood at $6.4 million in 2015, then fell by 15.36% to $5.4 million in 2016, then plummeted by 72.17% to $1.5 million in 2017.
  • Its Short-term Investments stands at $1.5 million for Q4 2017, versus $845389.0 for Q3 2017 and $845389.0 for Q2 2017.